PUK3 Ranitidine and Omeprazole Effect on Serum Phosphorus in Hemodidlysis Patients

Abstract

OBJECTIVES:To evaluate the effect of Ranitidine or Omeprazole in combination with CaCo3(as a phosphate binder) versus phosphate binders alone on the serum phosphorus level (PO4) in patients performing renal dialysis METHODS: Subjects were at Egypt. They were classified into three groups .Group I (38 subjects) served as control group in which they receivedCaCo3alone. Group II(39subjects) administrated CaCo3(2 gm-12gm three times daily) with Ranitidine (150mg twice daily).Group III(31subjects)received the same dose of CaCo3with Omeprazole (20 mg once daily).Blood samples were collected monthly for six months during the hemodialysis sessions. RESULTS: The obtained data revealed that patients in group II showed marked increase in serum (PO4) level at 4th, 5th and 6th months with significant increase in Calcium-Phosphorus product (CaxP). Significant decrease in serum level of Ca and Alkaline phosphatase (ALP). No significant change in serum PTH level .While in group III, the results show no significant change in serum level of Ca, PO4, PTH, and (CaxP) value with a significant decrease in serum ALP. CONCLUSIONS: Ranitidine co-administration with CaCo3 may aggravate hyperphosphatemia.Omeprazole co-administration with CaCo3 may have a beneficial role in minimizing complications in those patients.

Calcified Vocal Cord Nodule – A Unique Case Report

“…This can occur with or without a mineral imbalance. Abnormalities in calcium-phosphate balance develop early in the course of chronic kidney disease [5].…”